Subject(s)
Dementia/complications , Lung Diseases/complications , Rheumatic Diseases/complications , Sclera , Aged , Eye Diseases/etiology , Female , HumansABSTRACT
A 21-year-old female died in May 1976 from a pneumonic illness presenting with a right pleural effusion. Histopathology showed florid hyaline membrane disease of the left lung only, and focal pneumonitis in the lower lobe. Further investigations carried out by the Center for Disease Control, Atlanta, Georgia, showed that this patient had Legionnaires' disease infection, the first indigenous case diagnosed in Scotland. Post-mortem examination showed features differing from those in other published cases.
Subject(s)
Legionnaires' Disease/pathology , Adult , Female , Humans , Hyaline Membrane Disease/etiology , Hyaline Membrane Disease/pathology , Infant, Newborn , Legionnaires' Disease/complications , Lung/pathology , Pleural Effusion/etiology , ScotlandABSTRACT
In two cases of legionnaires' disease pneumonia was associated with severe cerebral disturbance. In one case legionnaires' disease was diagnosed retrospectively by serological methods, and in the other the development of similar cerebral symptoms in the course of pneumonia prompted a clinical diagnosis of legionnaires' disease and the institution of effective treatment.
Subject(s)
Aphasia/etiology , Ataxia/etiology , Hypesthesia/etiology , Legionnaires' Disease/complications , Aphasia/diagnosis , Ataxia/diagnosis , Erythromycin/administration & dosage , Female , Humans , Hypesthesia/diagnosis , Legionnaires' Disease/diagnosis , Legionnaires' Disease/drug therapy , Middle Aged , Retrospective StudiesSubject(s)
Legionnaires' Disease/epidemiology , Adult , Female , Humans , Italy , Pleural Effusion , ScotlandABSTRACT
Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoniazid (E+I). 63 patients in each continuation group were followed up for at least one year, and no relapses occurred. Continuation treatment with E+I was as effective and acceptable as that with R+I and was much less costly.
Subject(s)
Ethambutol/administration & dosage , Isoniazid/administration & dosage , Rifampin/administration & dosage , Tuberculosis, Pulmonary/drug therapy , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Time FactorsABSTRACT
Serum-levels of rifampicin were investigated in patients receiving rifampicin alone or with other antituberculosis drugs. 2 g of probenecid given 30 min before 300 mg of rifampicin did not result in raising serum levels to more than half those achieved with the standard 600 mg dose of rifampicin. Hence probenecid should not be used to reduce rifampicin dosage in antituberculosis therapy.
